Peter Almond’s health now hangs in the balance as the drug that was helping to improve his quality of life is not available on the NHS ...

Move Over, Vial. In a new titra/news/conference-coverage/donanemab-small-tweak-titration-big-gain-safetytion protocol (bottom ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...

Peter Almond finished a trial for donanemab in September having been on the drug for three years. Donanemab is one of the new “disease modifying” treatments for Alzheimer’s disease ...

Donanemab has been hailed as 'a new hope' in the fight against dementia, after studies showed it slowed the memory-robbing illness in its early stages. And today it got the green light from UK ...

Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new “disease modifying” treatments for Alzheimer’s disease ...

Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered. – What kind of ...

The costs of providing donanemab, including regular infusions and intensive monitoring for serious side effects, balanced against the relatively small benefit it provides to patients, means it cannot ...

Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.